Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

St. George Hospital, Kogarah

UZ Leuven, Leuven

Cancer Clinical Trials Centre, Austin Health, Level 4, Heidelberg

Genesis Care, Heidelberg

Monash Health, Clayton

UZ Gent, Ghent

Hospital San Pedro de Alcantara, Cáceres

North Shore Hematology Oncology Associates, East Setauket

Farmacia Studi Clinici, Rozzano

Istituto Clinico Humanitas, Rozzano

Centro de Investigación Medicina Especializada Sanitaria (CIMES), Málaga

Hospital Universitario Virgen de la Victoria, Málaga

Norton Cancer Institute, Louisville

Norton Diagnostic Center - Dupont, Louisville

Norton Women's and Children's Hospital, Louisville

University of Michigan Health System, Ann Arbor

Mayo Clinic, Rochester

Tulane Medical Center, New Orleans

City of Hope, Duarte

Parexel International, Billerica

Malopolskie Centrum Medyczne S.C., Krakow

Centrum Onkologii Ziemi Lubelskiej im. Sw. Jana z Dukli, Lublin

Centrum Onkologii Ziemi Lubelskiej im. Sw. Jana z Dukli Oddzial Hematologiczny, Lublin

Nzoz McD Voxel Osrodek Pet-Tk-Nmr, Krakow

NU-MED Centrum Diagnostyki i Terapii Onkologicznej Zamosc Sp. z o.o., Zamość

Samsung Medical Center Clinical Trial Pharmacy, Seoul

Samsung Medical Center, Seoul

The Christie NHS Foundation Trust, Manchester

The Christie Pathology Partnership, Manchester